Stealth BioTherapeutics Plans Exit After FDA Sends Mixed Signals
Stealth BioTherapeutics, the biotech equivalent of a cautious cat, is prepping to shut down after receiving what it called 'conflicting' signals from the FDA. Itâs like getting a yes, no, maybe so, and ÂŻ\_(ă)_/ÂŻ all in one letter. Developing a rare disease drug isnât for the faint of heart, but apparently trying to decode FDA feedback is a full-contact sport. The company said it's making 'contingency plans to close,' proving sometimes the biggest rare disease is surviving bureaucracy without a sequel to your disaster.
Share the Story
(1 of 3)When the FDA's feedback is so confusing even a biotech drug pitcher gives up and says 'plot twist: closing time.' Rare disease drugs? More like rare clarity.
Stealth BioTherapeutics just experienced the classic FDA mixed signal â like getting ghosted on a text but with your companyâs life. 'Itâs not you, itâs the ambiguous regulatory dance.'
Trying to get FDA approval from Stealth BioTherapeutics must feel like sending a message in a bottle tossed into a bureaucratic Bermuda Triangleâwhere rare diseases go to wait for clarity that never arrives.
Source: Statnews | Published: 8/5/2025 | Author: Ed Silverman
More Articles in Health
Trump Extends Ceasefire Because Iran's Drama Series Needs Another Season
OpenAI CEOâs $27M Mansion Molotoved Amid AI Lab Soap Opera
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Couple Rejects Costco Bulk, Returns to European Grocery Steps and Sanity
Woman Befriends Octogenarian, Learns Aging Is Just 'Old Lady' Bluntness
Womanâs Routine Eye Surgery Turns Into Unplanned MRI Brain Tumor Scare Roadshow
Health Secretary Trades Vaccines for Vegetable Advocacy and Congressional Grousing
Doctors Prescribe Fishing RodsâBecause Pills Canât Cast a Line
